{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:51:46Z","timestamp":1780638706478,"version":"3.54.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>The development of Parkinson\u2019s disease (PD) involves the degeneration of dopaminergic neurons caused by oxidative stress. Accumulating clinical evidence indicates that high blood levels of uric acid (UA), an intrinsic antioxidative substance, are associated with reduced risk of PD. However, this hypothesis has not been confirmed by in-vivo experiments. The present study investigated the effects of UA on behavioral abnormalities in the development of PD. We used unilateral 6-hydroxydopamine-lesioned mice, which were fed on a diet containing 1% UA and 2.5% potassium oxonate (an uricase inhibitor) to induce hyperuricemia. A significant elevation in UA levels was found in groups that were fed a UA diet. The 6-hydroxydopamine-lesioned mice showed impaired rotarod performance and increased apomorphine-induced contralateral rotations. These behavioral abnormalities were significantly reversed by feeding a UA diet for 1 week before and 5 weeks after surgery (subchronic hyperuricemia). These behavioral improvements occurred in parallel with recovery of tyrosine hydroxylase protein levels in the lesioned striatal side. The present study with a dietary hyperuricemia mice model confirms that UA exerts a neuroprotective effect on dopaminergic neuronal loss, improving motor dysfunction and ameliorating PD development.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000413","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T02:02:34Z","timestamp":1527732154000},"page":"89-94","source":"Crossref","is-referenced-by-count":8,"title":["Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson\u2019s disease"],"prefix":"10.1097","volume":"30","author":[{"given":"Akio","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Dohgu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuko","family":"Takata","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhisa","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Fukae","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fukuoka University School of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fukuoka University School of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230910","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","article-title":"Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis","volume":"78","author":"Ames","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"key":"R2-20230910","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/mds.21502","article-title":"Low plasma uric acid level in Parkinson\u2019s disease","volume":"22","author":"Annanmaki","year":"2007","journal-title":"Mov Disord"},{"key":"R3-20230910","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archneurol.2009.247","article-title":"Urate as a predictor of the rate of clinical decline in Parkinson disease","volume":"66","author":"Ascherio","year":"2009","journal-title":"Arch Neurol"},{"key":"R4-20230910","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbi.2009.09.001","article-title":"Minimal penetration of lipopolysaccharide across the murine blood\u2013brain barrier","volume":"24","author":"Banks","year":"2010","journal-title":"Brain Behav Immun"},{"key":"R5-20230910","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.peptides.2010.09.011","article-title":"Insulin detemir is not transported across the blood\u2013brain barrier","volume":"31","author":"Banks","year":"2010","journal-title":"Peptides"},{"key":"R6-20230910","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1073\/pnas.1217296110","article-title":"Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration","volume":"110","author":"Chen","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"R7-20230910","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1471-4159.2012.07820.x","article-title":"Protection of dopaminergic cells by urate requires its accumulation in astrocytes","volume":"123","author":"Cipriani","year":"2012","journal-title":"J Neurochem"},{"key":"R8-20230910","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1042\/bj2350747","article-title":"Uric acid\u2013iron ion complexes. A new aspect of the antioxidant functions of uric acid","volume":"235","author":"Davies","year":"1986","journal-title":"Biochem J"},{"key":"R9-20230910","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.20663","article-title":"Serum uric acid levels and the risk of Parkinson disease","volume":"58","author":"de Lau","year":"2005","journal-title":"Ann Neurol"},{"key":"R10-20230910","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/jnc.12809","article-title":"Elevation of striatal urate in experimental models of Parkinson\u2019s disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration?","volume":"131","author":"De Luca","year":"2014","journal-title":"J Neurochem"},{"key":"R11-20230910","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3233\/JPD-140353","article-title":"Serum uric acid concentration is linked to wearing-off fluctuation in Japanese Parkinson\u2019s disease patients","volume":"4","author":"Fukae","year":"2014","journal-title":"J Parkinsons Dis"},{"key":"R12-20230910","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.0000000000002351","article-title":"Prospective study of plasma urate and risk of Parkinson disease in men and women","volume":"86","author":"Gao","year":"2016","journal-title":"Neurology"},{"key":"R13-20230910","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/jnc.12038","article-title":"Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson\u2019s disease: linking to Akt\/GSK3beta signaling pathway","volume":"123","author":"Gong","year":"2012","journal-title":"J Neurochem"},{"key":"R14-20230910","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/ana.410440712","article-title":"Understanding cell death in Parkinson\u2019s disease","volume":"44","author":"Jenner","year":"1998","journal-title":"Ann Neurol"},{"key":"R16-20230910","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40478-017-0470-4","article-title":"Transmission of alpha-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson\u2019s disease?","volume":"5","author":"Matsumoto","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"R17-20230910","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/aje\/kwq195","article-title":"Plasma urate and Parkinson\u2019s disease in women","volume":"172","author":"O\u2019Reilly","year":"2010","journal-title":"Am J Epidemiol"},{"key":"R19-20230910","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archneur.2008.65.6.nct70003","article-title":"Serum urate as a predictor of clinical and radiographic progression in Parkinson disease","volume":"65","author":"Schwarzschild","year":"2008","journal-title":"Arch Neurol"},{"key":"R20-20230910","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","article-title":"Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial","volume":"71","author":"Schwarzschild","year":"2014","journal-title":"JAMA neurology"},{"key":"R21-20230910","doi-asserted-by":"crossref","first-page":"e12013","DOI":"10.14814\/phy2.12013","article-title":"Paracellular route is the major urate transport pathway across the blood\u2013placental barrier","volume":"2","author":"Uehara","year":"2014","journal-title":"Physiol Rep"},{"key":"R22-20230910","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neulet.2011.10.075","article-title":"Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action","volume":"506","author":"Zhu","year":"2012","journal-title":"Neurosci Lett"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008877-201902000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T08:06:19Z","timestamp":1694333179000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008877-201902000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000413","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}